Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Yf-H-2015005, a New CXCR4 Antagonist, in the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma: A Randomized-Controlled Phase 3 Study

Blood (2019) 134 (Supplement_1): 590.

https://doi.org/10.1182/blood-2019-125456

Published: 2019

Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, DO, Ying Huang, MS, MA, Akwasi Agyeman, Amy S. Ruppert, MAS, PhD, Boyu Hu, MD, Natalie Turner, APRN, Renee Vadeboncoeur, MSN, APRN, Kerry A Rogers, MD, Seema A. Bhat, MD, Basem M. William, MRCP,MD, Samantha Jaglowski, MDMPH, Hank Lockman, Martha Glenn, MD, Rosa Lapalombella, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 4310.

https://doi.org/10.1182/blood-2019-124544

Published: 2019

Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5299.

https://doi.org/10.1182/blood-2019-124997

Published: 2019

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

Journal Articles

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

Paolo Caimi, MD, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Shui He, PhD, David Ungar, MD, Jay Feingold, MD PhD, Kirit M. Ardeshna, MA MD FRCP FRCPath, John Radford, MD FRCP, Melhem Solh, MD, Leonard Heffner, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2018-99-118133

Published: 2018

Journal Articles

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Mateo Mejia Saldarriaga, MD, Amir Steinberg, MD, Adam F. Binder, MD

Blood (2018) 132 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2018-99-112652

Published: 2018

Journal Articles

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Masahiro Sekimizu, MD PhD, Reiji Fukano, MD PhD, Ilseung Choi, MD PhD, Akiko Kada, PhD, Akiko Saito, MD, Ryuta Asada, PhD, Tetsuya Mori, MD PhD, Hirokazu Nagai, MD PhD

Blood (2018) 132 (Supplement 1): 2924.

https://doi.org/10.1182/blood-2018-99-112708

Published: 2018

Journal Articles

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Giovanni Palladini, MDPhD, Ute Hegenbart, Paolo Milani, MD, Marco Basset, MD, Christoph Kimmich, MD, Francesca Russo, MD, Tilman Bochtler, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Stefan Schönland, MD

Blood (2017) 130 (Supplement 1): 1759.

https://doi.org/10.1182/blood.V130.Suppl_1.1759.1759

Published: 2017

Journal Articles

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Joseph Tuscano, MD, Susan Groshen, PhD, Denice Tsao-Wei, Emanual Maverakis, MD, Paul R. Kaesberg, MD, Tanya Siddiqi, MD, Leslie Popplewell**, MD, Sikander Ailawadhi, Myo Htut, Robert W. Chen, MD, Mark Kirschbaum, MD, Mark T. Schroeder, MD, Brian A Jonas, MD PhD, Ted Wun, MD FACP, FRCPA, Neil Palmisiano, MD, David F. Claxton, Edward Newman, PhD

Blood (2017) 130 (Supplement 1): 4086.

https://doi.org/10.1182/blood.V130.Suppl_1.4086.4086

Published: 2017

Journal Articles

Elevation of Serum Pro-Brain Natriuretic Peptide in G-CSF Stimulated Hematopoietic Progenitor Cell Donors

Montemayor Celina, MD PhD, Kamille A West, MD, Anne Eder, MD, Cathy Cantilena, MD, Harvey G. Klein, MD

Blood (2016) 128 (22): 2185.

https://doi.org/10.1182/blood.V128.22.2185.2185

Published: 2016

Journal Articles

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Mohamad Jawhar, MD, Juliana Schwaab, MD, Manja Meggendorfer, PhD, Nicole Naumann, Hans-Peter Horny, MD, Karl Sotlar, MD, Torsten Haferlach, MD, Karla Schmitt, MD, Alice Fabarius, PhD, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD, Andreas Reiter, MD

Blood (2016) 128 (22): 3109.

https://doi.org/10.1182/blood.V128.22.3109.3109

Published: 2016

Journal Articles

Induction Therapy with Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplantation for Systemic Light Chain Amyloidosis: Our Experience

Sandeep Jain, MD MRCP, Luciano J Costa, MD PhD, Robert K Stuart, MD, Saurabh Chhabra, MD, Alice Mims, MD, Yubin Kang, MD

Blood (2014) 124 (21): 5907.

https://doi.org/10.1182/blood.V124.21.5907.5907

Published: 2014

Journal Articles

Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome

Giovanni Palladini, MD PhD, Paolo Milani, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2014) 124 (21): 3361.

https://doi.org/10.1182/blood.V124.21.3361.3361

Published: 2014

Journal Articles

A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage

Anjali S. Advani, MD, Anthony S. Stein, MD, Hagop M. Kantarjian, MD, Andrei R. Shustov, MD, Daniel J. DeAngelo, MD PhD, Revathi Ananthakrishnan, Katherine Liau, Erik Vandendries, MD, Wendy Stock, MD

Blood (2014) 124 (21): 2255.

https://doi.org/10.1182/blood.V124.21.2255.2255

Published: 2014

Journal Articles

Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease

Loredana Santo, Diana Cirstea, Bin Wang, Tso-Pang Yao, Joy Y. Wu, Peter Waterman, Derrick Jeon, Mary Bouxsein, Leeann Louis, Sutada Lotinun, Roland Baron, Homare Eda, Neeharika Nemani, Anuj Mahindra, Andrew J. Yee, Teru Hideshima, Kenneth C. Anderson, Simon S Jones, Noopur Raje, MD

Blood (2012) 120 (21): 328.

https://doi.org/10.1182/blood.V120.21.328.328

Published: 2012

Journal Articles

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Diana Cirstea, MD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Scott Rodig, MD, PhD, Miriam Canavese, PhD, James Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2908.

https://doi.org/10.1182/blood.V118.21.2908.2908

Published: 2011

Journal Articles

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD, Joseph Leach, MD, W. Christopher Ehmann, MD, Kiyoshi Ando, MD, PhD, Kiyohiko Hatake, MD, PhD, Kensei Tobinai, MD, PhD, Tatyana Feldman, MD, Steven Hua, Angela DG Volkert, Erik R. Vandendries, MD, PhD, Michinori Ogura, MD, PhD

Blood (2010) 116 (21): 430.

https://doi.org/10.1182/blood.V116.21.430.430

Published: 2010

Journal Articles

HLA-Haploidentical Hematopoietic Stem Cell Transplantation In An Infant with Malignant Infantile Osteopetorosis.

Taichi Omachi, Hirohide Kawasaki, Yukihiro Noda, Kazunari Kaneko

Blood (2010) 116 (21): 4585.

https://doi.org/10.1182/blood.V116.21.4585.4585

Published: 2010

Journal Articles

A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms

Animesh Pardanani, MBBS, PhD, Geeta George, P.A.-C, Terra Lasho, MT, (ASCP), William J. Hogan, MBBCH, BA, MRCPI, Mark R. Litzow, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Rose Fida, Chris Burns, Gregg D Smith, Ayalew Tefferi, MD

Blood (2010) 116 (21): 460.

https://doi.org/10.1182/blood.V116.21.460.460

Published: 2010

Journal Articles

Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.

Shaji Kumar, MD, Luis F Porrata, MD, Stephen M. Ansell, MD, PhD, Joseph P Colgan, MD, Betsy LaPlant, Morie A Gertz, MD, David J Inwards, MD, Patrick B Johnston, MD, PhD, Thomas Haberman, MD, Ivana N Micallef, MD, Grzegorz S. Nowakowski, MD, Thomas E. Witzig, MD

Blood (2010) 116 (21): 2802.

https://doi.org/10.1182/blood.V116.21.2802.2802

Published: 2010

NARROW

Yf-H-2015005, a New CXCR4 Antagonist, in the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma: A Randomized-Controlled Phase 3 Study

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Elevation of Serum Pro-Brain Natriuretic Peptide in G-CSF Stimulated Hematopoietic Progenitor Cell Donors

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Induction Therapy with Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplantation for Systemic Light Chain Amyloidosis: Our Experience

Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome

A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage

Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

HLA-Haploidentical Hematopoietic Stem Cell Transplantation In An Infant with Malignant Infantile Osteopetorosis.

A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms

Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only